Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Invitrogen™ Complement C5 (Eculizumab Biosimilar) Recombinant Human Monoclonal Antibody
GREENER_CHOICE

Catalog No. PIMA541700
Change view
Click to view available options
Quantity:
100 μg
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
PIMA541700 100 μg
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
This item is not returnable. View return policy
Catalog No. PIMA541700 Supplier Invitrogen™ Supplier No. MA541700
Add to Cart
Add to Cart
This item is not returnable. View return policy

Human Recombinant Monoclonal Antibody

Endotoxin level <0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt. This product is a Humanized mouse antibody.

C5 (Complement C5) is a Protein Coding gene. Diseases associated with C5 include Complement Component 5 Deficiency and Eculizumab, Poor Response To. Among its related pathways are GPCR downstream signalling and Acquired partial lipodystrophy / Barraquer-Simons syndrome. Gene Ontology (GO) annotations related to this gene include signaling receptor binding and endopeptidase inhibitor activity. An important paralog of this gene is C3. This gene encodes a component of the complement system, a part of the innate immune system that plays an important role in inflammation, host homeostasis, and host defense against pathogens. The encoded preproprotein is proteolytically processed to generate multiple protein products, including the C5 alpha chain, C5 beta chain, C5a anaphylatoxin and C5b. The C5 protein is comprised of the C5 alpha and beta chains, which are linked by a disulfide bridge. Cleavage of the alpha chain by a convertase enzyme results in the formation of the C5a anaphylatoxin, which possesses potent spasmogenic and chemotactic activity, and the C5b macromolecular cleavage product, a subunit of the membrane attack complex (MAC). Mutations in this gene cause complement component 5 deficiency, a disease characterized by recurrent bacterial infections. Alternative splicing results in multiple transcript variants.
TRUSTED_SUSTAINABILITY

Specifications

Antigen Complement C5 (Eculizumab Biosimilar)
Applications ELISA
Classification Recombinant Monoclonal
Concentration 3.38 mg/mL
Conjugate Unconjugated
Formulation PBS with no preservative; pH 7.4
Gene C5
Gene Accession No. P01031
Gene Alias anaphylatoxin; anaphylatoxin C5; anaphylatoxin C5a analog; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4; C5; C5a; C5a anaphylatoxin; C5b; C5D; Complement C5; Complement C5 alpha chain; Complement C5 alpha' chain; Complement C5 beta chain; complement component 5; CPAMD4; ECLZB; Hc; He; hemolytic complement; prepro-C5; RGD1561905
Gene Symbols C5
Host Species Human
Immunogen Human C5.
Purification Method Protein A/G
Quantity 100 μg
Regulatory Status RUO
Primary or Secondary Primary
Gene ID (Entrez) 727
Target Species Human
Content And Storage -20°C, Avoid Freeze/Thaw Cycles
Product Type Antibody
Form Liquid
Isotype IgG2 κ, IgG4 κ
Target Molecule Chemical
Show More Show Less
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.